• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » LabCorp to Acquire Tandem Labs

LabCorp to Acquire Tandem Labs

January 28, 2008
CenterWatch Staff

Burlington, N.C.-based LabCorp has signed an agreement to acquire the bioanalytical services company Tandem Labs for an undisclosed amount. Tandem performs analytical lab work for drugs in all stages of development including discovery, preclinical, and clinical. Founded in 1981 as Northwest Toxicology Consultants, the company initially operated as a clinical toxicology reference laboratory.

LabCorp is the second largest reference laboratory testing company in the U.S., but its client base is primarily hospitals, clinics and government agencies. It offers tests ranging from routine blood analyses to HIV and genomic testing. Tandem Labs will join the Esoterix clinical trials group at LabCorp and maintain both its name and management.

LabCorp has revenues of $3.5 billion and 23,500 employees. The company has a network of 36 laboratories and 1,300 service sites.

The bulk of LabCorp’s testing business involves performing quick routine tests on more than 360,000 patient specimens daily, serving hospitals, clinics, doctor’s offices, law enforcement agencies and medical testing centers. As with most reference labs, its most frequently requested tests include blood chemistry analyses, urinalyses, blood cell counts, Pap, HIV, and substance-abuse tests.

LabCorp’s central laboratory business generates 2% of its revenue. The company has a 4% share of the central labs market, holding steady since 2003. Its clinical testing headquarters is located in Raritan, N.J., and its European headquarters, in Belgium.

The deal is expected to close in the first quarter of 2008.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing